FDA: Reviewing controversial device OK

The FDA said it will re-examine its decision to approve a knee-surgery device last December over the objections of several scientists and managers at the agency, according to a letter from the agency that the Senate Finance Committee reviewed Monday. Report

Suggested Articles

AstraZeneca
Pharma

NICE shuts out AZ's Tagrisso—and dings J&J's Stelara, too

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

by Carly Helfand
jnj
Pharma

J&J's expects last year's copycat pain to 'bleed into 2020'

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

by Eric Sagonowsky
Lonza headquarters
Manufacturing

Lonza's next CEO to be pharma or biotech vet, chairman says

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.

by Eric Palmer